Fig. 1.

Patient disposition. ^aAll dates ranged from the earliest initiation date to February 1, 2019. ABA abatacept, ACPA anti-citrullinated protein antibody, CDAI Clinical Disease Activity Index, RTX rituximab, TCZ tocilizumab, TOFA tofacitinib. Figure adapted from Harrold LR, et al. ACR/ARP Annual Meeting; November 8–13, 2019; abstract number: 1386. Reprinted from ACR Convergence held November 8–13, 2019. The American College of Rheumatology does not guarantee, warrant, or endorse any commercial products or services. Reprinted by Springer